Loading, please wait...
| REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, November 18, 2020
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Alexa Townsend, Pharm.D.
Multi-system Inflammatory Disease Management in Childre |
Rachel Watson, Pharm.D.
Use of PCSK9 Inhibitors Following an Acute Coronary Event |
James Reimer, Pharm.D.
The Impact of Tranexamic Acid on Mortality and Neurologic Outcomes in Traumatic Brain Injury Patients |
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Alec Kuhn, Pharm.D.
Safety Considerations of Intravenous Iron in Cancer and Chemotherapy Induced Iron Deficiency Anemia |
Patrick Ladapo, Pharm.D.
Optimal Treatment Duration for Uncomplicated Gram-negative Bacteremia |
Erin Houry, Pharm.D.
Continuous Versus Intermittent Proton Pump Inhibitor Therapy for Upper Gastrointestinal Bleeds |
Please join us for the fourth Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, November 13, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 25, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 18, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
Multi-system Inflammatory Disease is a rare complication of COVID-19 infection. Identification and proper management of Multi-system Inflammatory Disease in Children (MIS-C) is of high importance as the COVID-19 pandemic continues. Due to its rarity and similarities to Kawasaki Disease, education on MIS-C management will be helpful to pharmacists and other health professionals to properly treat one of our most vulnerable populations. After this seminar, attendees will be able to properly identify manifestations, understand psychophysiology, properly diagnose, and manage MIS-C.
Objectives
- Select the appropriate first line management of Multi-system Inflammatory Disease in Children
- Compare and contrast MIS-C from Kawasaki Disease
- Identify the appropriate diagnoses of MIS-C in a clinical case
Speaker(s)/Author(s)
|
Alexa Townsend, Pharm.D. |
Activity Number
0033-0000-20-076-L01-P
Date:
11/18/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 337 and Virtually
Proprotein convertase substilisin/kexin type 9 (PCSK9) inhibitors were added to the ACC/AHA guidelines for primary prevention of atherosclerotic cardiovascular disease, but their role in secondary prevention is less clear. The current guidelines that outline the place in therapy for PCSK9 inhibitors will be discussed. Additionally, the current trials and data surrounding the efficacy of PCKS9 inhibitors will be reviewed and analyzed to help assist pharmacists in determining the patient population that may benefit from the use of PCSK9 inhibitors for secondary prevention of ASCVD events. The overall goal of this presentation will be to help pharmacists better understand the use of PCSK9 inhibitors in reducing secondary coronary events and improve patient health outcomes.
Objectives
- Based on the literature available, identify the main conclusions of the use of PCSK9 inhibitors for the use of secondary prevention of acute coronary events
- Describe the place in therapy for PCSK9 inhibitors in the prevention of secondary acute coronary events
- Identify patients who may benefit from the use of PCSK9 inhibitors as part of their lipid-lowering therapy to reduce the risk of secondary acute coronary events
Speaker(s)/Author(s)
|
Rachel Watson, Pharm.D. |
Activity Number
0033-0000-20-071-L01-P
Date:
11/18/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 406 and Virtually
This continuing education seminar will examine traumatic brain injury (TBI) and the potential use of tranexamin acid (TXA) to improve patient outcomes. The presentation will begin with a brief overview of TBI and the classifications of severity followed by the pathophysiology, coagulopathy and clinical management of patients with TBI. Discussions will then focus on TXA including mechanism of action, treatment adverse effects, as well as pharmacokinetic and pharmacodynamic properties. Next the presentation will explore current literature for using TXA in TBI patients and conclude with an evaluation of how TXA fits into treatment algorithms. Evaluation of audience comprehension will be assessed throughout the presentation in the form of multiple-choice questions.
Objectives
- Describe the underlying pathophysiology and coagulopathy in traumatic brain injury (TBI)
- Identify the rationale of administering tranexamic acid (TXA) in bleeding casualties
- Explain the potential role of TXA in patients with TBI
Speaker(s)/Author(s)
|
James Reimer, Pharm.D. |
Activity Number
0033-0000-20-072-L01-P
Date:
11/18/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
Cancer and chemotherapy associated iron deficiency anemia is a known and chronic problem. Currently, IV iron is available to treat iron deficiency anemia in the cancer population. Historically, guidelines did not recommend the use of IV iron in this population due to lack of evidence surrounding clinical application. However, with recent trials testing the utilization of IV iron in cancer patients, there is enough evidence to support its efficacy and short-term safety. Long-term safety data of IV iron in this population is poor. Animal and epidemiological studies have suggested that IV iron may play a role in tumor progression, thus raising concern for further carcinogenesis or tumor proliferation in cancer patients. The objective of this lecture is to educate pharmacists on the literature surrounding long-term safety of IV iron in cancer patients and develop an evidence-based recommendation on the use of IV iron cancer/chemotherapy associated iron deficiency anemia.
Objectives
- Discuss the prevalence and causes of cancer/chemotherapy associated iron deficiency anemia
- Summarize current evidence regarding long-term safety implications of IV iron use in cancer/chemotherapy induced iron deficiency anemia
Speaker(s)/Author(s)
|
Alec Kuhn, Pharm.D. |
Activity Number
0033-0000-20-075-L01-P
Date:
11/18/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Bloodstream infections are the 11th most common cause of death in the United States, leading to over 40,000 deaths yearly. Gram-negative bacteria account for nearly one-half of community acquired bloodstream infections and one-third of hospital cases.1 Uncomplicated gram-negative bloodstream infections, while not precisely defined in the literature, generally refers to bloodstream infections secondary to focal infections such as skin and soft-tissue infections, pneumonia, pyelonephritis, or urinary tract infections, with the most common etiology being E. Coli.3 Current practice guidelines lack sufficient detail to guide evidence-based decisions on uncomplicated gram-negative bacteremia bloodstream infection treatment durations. This uncertainty frequently results in prolonged treatment durations. Whereas shorter durations may reduce drug-related adverse events, duration of hospitalization, and the emergence of antibacterial resistance.5 Recently, emerging evidence supports a shorter overall duration for hosptialized patients with uncomplicated bacteremia. The seminar will define uncomplicated gram-negative bloodstream infections and discuss the recent literature, and lastly provide a summary to assist providers in recommending optimal treatment duration in a patient with uncomplicated gram-negative bloodstream infections.
Objectives
- Compare and contrast complicated and uncomplicated gram-negative bacteremia
- Recommend appropriate therapy duration for uncomplicated gram-negative bacteremia based on clinical presentation
Speaker(s)/Author(s)
|
Patrick Ladapo, Pharm.D. |
Activity Number
0033-0000-073-L01-P
Date:
11/18/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ABR 406 and Virtually
This continuing education seminar will review background information and summarize available literature to determine whether intermittent proton pump inhibitor (PPI) therapy can be used in place of continuous infusion proton pump inhibitor therapy in upper gastrointestinal bleeds. The presentation will begin with the epidemiology/etiology of upper gastrointestinal bleeds. The presentation will then describe the normal anatomy and physiology of the gastrointestinal tract, including the role of parietal cells in creating an acidic environment. The pathophysiology of upper gastrointestinal bleeds will be explained, and the problematic nature of the acidic environment will be emphasized. The guidelines for nonvariceal upper gastrointestinal bleeds will be reviewed. PPI therapy will be discussed and the mechanism of action in increasing intragastric pH explained. Literature comparing continuous and intermittent PPIs in gastrointestinal bleeds will be reviewed. Intragastric pH studies will be reviewed first, followed by outcome studies and meta-analyses. An intragastric pH study and outcome study will be discussed in detail, as well as a recent retrospective outcome study. The presentation will conclude with an evaluation of how intermittent PPI therapy fits into the treatment algorithm for upper gastrointestinal bleeds. The need for future research will be emphasized. Evaluation of audience comprehension will be assessed throughout the presentation in the form of multiple-choice questions.
Objectives
- Explain how Helicobacter pylori, nonsteroidal anti-inflammatory drugs, and stress-related mucosal damage cause peptic ulcers and upper gastrointestinal bleeds
- Describe the mechanism of action of proton pump inhibitors in the treatment of upper gastrointestinal bleeds
- Select an appropriate treatment regimen for patients with upper gastrointestinal bleeds
Speaker(s)/Author(s)
|
Erin Houry, Pharm.D. |
Activity Number
0033-0000-20-070-L01-P
Date:
11/18/20
Time:
01:00 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
